Bladder perfusion pharmaceutical composition, preparation method therefor and application thereof
US-2024398841-A1 · Dec 5, 2024 · US
Imidazoquinolines as dual lipid kinase and mTOR inhibitors
US9370508B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9370508-B2 |
| Application number | US-52533308-A |
| Country | US |
| Kind code | B2 |
| Filing date | Feb 19, 2008 |
| Priority date | Feb 20, 2007 |
| Publication date | Jun 21, 2016 |
| Grant date | Jun 21, 2016 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The invention relates to the use of compounds of formula (I) in the treatment of mammalian target of rapamycin (mTOR) kinase dependent diseases, methods of use of said compounds in the treatment of said diseases in a warm-blooded animal, especially a human, pharmaceutical preparations comprising said compounds for the treatment of said diseases and said compounds for use in the treatment of said diseases.
First claim
Opening claim text (preview).
The invention claimed is: 1. A method of inhibiting mammalian target of rapamycin (mTOR) kinase in a patient with mTOR kinase dependent disease comprising administering a therapeutically effective amount of a compound 2-methyl-2-[4-(3-methyl-2-oxo-8-quinolin-3-yl-2,3-dihydro-imidazo[4,5-c]quinolin-1-yl)-phenyl]-propionitrile, or a pharmaceutically acceptable salt thereof, to a patient in need thereof wherein said mTOR kinase dependent disease is selected from the group consisting of muscle wasting, atrophy and cachexia.
Assignees
Inventors
Classifications
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9370508B2 cover?
- The invention relates to the use of compounds of formula (I) in the treatment of mammalian target of rapamycin (mTOR) kinase dependent diseases, methods of use of said compounds in the treatment of said diseases in a warm-blooded animal, especially a human, pharmaceutical preparations comprising said compounds for the treatment of said diseases and said compounds for …
- Who is the assignee on this patent?
- Garcia-Echeverria Carlos, Nicklin Paul Leslie, Murphy Leon, and 5 more
- What technology area does this patent fall under?
- Primary CPC classification A61K31/4745. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Jun 21 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).